Detalhe da pesquisa
1.
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy.
Nature
; 615(7953): 697-704, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36890230
2.
CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes.
Nat Commun
; 15(1): 1244, 2024 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38336975
3.
A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer.
Cancer Res Commun
; 3(8): 1628-1637, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37621406
4.
Infusion Product TNFα, Th2, and STAT3 Activities Are Associated with Clinical Responses to Transgenic T-cell Receptor Cell Therapy.
Cancer Immunol Res
; 11(12): 1589-1597, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871333
5.
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
Nat Med
; 29(9): 2278-2285, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37592104
6.
Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade.
J Immunother Cancer
; 11(5)2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37156551
7.
Remodeling of the tumor microenvironment through PAK4 inhibition sensitizes tumors to immune checkpoint blockade.
Cancer Res Commun
; 2(10): 1214-1228, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588582
8.
PAK4 inhibition improves PD-1 blockade immunotherapy.
Nat Cancer
; 1(1): 46-58, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-34368780
9.
Autoantibody Landscape in Patients with Advanced Prostate Cancer.
Clin Cancer Res
; 26(23): 6204-6214, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32967941
10.
Publisher Correction: PAK4 inhibition improves PD-1 blockade immunotherapy.
Nat Cancer
; 1(2): 264, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35122015